Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenFleet Out-Licenses CDK9 Inhibitor to Sellas in $150 Million Deal

publication date: Apr 6, 2022

Shanghai GenFleet Therapeutics out-licensed global rights (ex-Greater China) for a small molecule cyclin-dependent kinase 9 (CDK9) inhibitor to New York’s Sellas Life Sciences in a $150 million deal. GFH009, currently in Phase I trials in the US and China, has a unique mechanism of action that leads to lower toxicity and more potent efficacy, according to GenFleet’s read of the initial pharmacokinetic data in the Phase I trial. In 2014, Sellas was formed to develop an inhibitor of the WT1 protein, which is present in many cancers. Sellas in-licensed the drug from Memorial Sloan Kettering Hospital. More details....

Stock Symbol: (NSDQ: SLS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here